Clinical trial
Exploratory Study to Assess Utility of RetiSpec Artificial Intelligence Powered Retinal Imaging Solution in Detecting Amyloid Pathology in United Arab Emirates Nationals With Mild Impairment of Cognition
NCT07254234 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Exploratory Study to Assess Utility of RetiSpec Artificial Intelligence Powered Retinal Imaging Solution in Detecting Amyloid Pathology in United Arab Emirates Nationals With Mild Impairment of Cognition
- Lead sponsor
- Eli Lilly and Company
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- September 23, 2026
- Completion date
- September 30, 2027
- Enrollment
- 200 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.